J&J's Zytiga aiming for $910M in sales; Actelion adds COO to org chart;

@FiercePharma: Once-feared prosecutor now defends firms. Report | Follow @FiercePharma

> Johnson & Johnson's new drug Zytiga is set to earn peak-year sales of $910 million in major world markets from its use in the treatment of metastatic castrate-resistant prostate cancer, according to new forecasts. Item

> Actelion is changing its management structure, including appointing a chief operating officer, meeting some of the demands of activist investor Elliott Advisors. News

> The U.S. Supreme Court, in a ruling that limits the patent rights of research universities, threw out Stanford University's suit against a Roche Holding AG unit over methods for testing the effectiveness of AIDS treatments. Article

> India's Elder Pharmaceuticals plans to launch five products, including its top domestic brands such as calcium-loaded "Shelcal," in Europe this fiscal year in a bid to increase overseas revenue. Report

> Pushed to the limit at its manufacturing plants and eyeing production of a Parkinson's disease drug for GlaxoSmithKline, Impax Laboratories is undertaking a $52 million expansion of its year-old Taiwan facility. Story

> India's Dr. Reddy's Laboratories launched three generic drugs in the U.S., including a copycat version of the Alzheimer's drug Aricept and a generic version of the antidepressant Effexor XR. News

> APP Pharmaceuticals, a member of the Fresenius Kabi Group of companies, is set to market the breast cancer drug Letrozole in the U.S. following FDA approval. Item

> U.K. contract manufacturer SCM Pharma has secured around £1.2 million ($1.97 million) of new business over the last few months as it looks to accelerate its ongoing growth. Article

> India's self-regulatory draft code for putting an end to unethical marketing practices by pharma companies will be made mandatory if not adhered to by industry, the Indian government said. Report

Biotech News

@FierceBiotech: Experimental oral contraceptive looks promising for men. Story | Follow @FierceBiotech

@JohnCFierce: Sanofi ran a sub-group analysis on iniparib on the Ph3 failure and found 10.8 overall survival vs 8.1 month on chemo. News | Follow @JohnCFierce  

> Exelixis shares slide as CEO cheers a mid-stage prostate cancer success. News 

> Pfizer looks to electronics to streamline trials. Story

> Cancer pacts sizzle as developers start to team early on combos. Article 

> Sanofi preps for new pivotal trial of a blockbuster hopeful. Report 

Biotech Research News

> Anti-pain peptide a possible alternative to addictive opioids. Item 

> OCD appears to be genetic, but hoarding likely environmental. Article

> Nail-fungus drug also helps prostate cancer patients. Report 

> Obesity vaccine would suppress hunger hormone. Story 

Manufacturing News

> Impax reveals warning letter related to drug recall. News

> Chinese plant spews toxins into air, water. Report 

> FDA steps in to prevent drug shortages. Article

> Alli counterfeiter gets 87 months. Item

> Cargo theft hype masks pharma containment efforts. News

And Finally... Martin Mireles says his mother was not happy with his tongue piercing: It didn't fit his image as a former church youth leader. But it was for research. Paralyzed from a spinal cord injury since he was shot in the neck almost two decades ago, he was recently fitted with a magnetic stud that allows him to steer his wheelchair with his tongue. Report